Joshua Henderson

The CURE GM1 FOUNDATION’s mission is to fund research for the benefit of all those who suffer from GM1 gangliosidosis. The foundation has extremely minimal overhead costs with the maximum amount possible being allocated towards advancing treatments. This nonprofit organization was founded by parents of children who suffer from GM1 who seek to save the lives of all those who suffer from this wretched condition. The Cure GM1 Foundation is dedicated to directly funding research for a cure for GM1 gangliosidosis – a lysosomal storage disease that attacks the brain and spinal cord, and is always fatal in children. GM1 is a progressive and degenerative condition with an extremely broad and debilitating array of symptoms and complications.

Cureious works with early-stage healthcare innovators to accelerate commercial traction in biopharma and rare disease. We partner with lean, often founder-led commercial teams to expand BD capacity, open doors in pharma, and put the right processes in place before adding headcount. Our risk-sharing, outcomes-based model aligns incentives and ties our success directly to measurable results. What we do: - Go-to-Market & Expansion – Enter new markets, geographies, or therapeutic areas with clarity. - Strategic Partnerships – Engage advocacy groups, research sites, and channel partners. - AI-Driven Workflows – Automate BD and sales processes to scale impact without extra hires. - Deal Acceleration – Unblock stalled opportunities and advance must-win deals. Who We Work With Founders and small commercial teams looking to access biopharma and rare disease markets, where deep networks and precise execution matter. This includes: - AI-driven research platforms - Real-world evidence solutions - Digital health tools - Specialty drug developers Why Cureious: We thrive in the ambiguity of the early stages, where stakes are high and progress must be efficient. Our mix of curiosity, established industry relationships, and hands-on execution turns early wins into repeatable momentum.

StageNext invests in companies led by seasoned women entrepreneurs. Our vision is to establish StageNext as the strategic co-investor of choice for the entrepreneurs we back, the lead investors we follow, and the networks who refer their companies to us.

Springboard accelerates the growth of entrepreneurial companies led by women through access to essential resources and a global community of experts. We are a leading network of influencers, investors, and innovators dedicated to building high-growth companies led by women who are transforming industries. The measure of our success is in the results. Since we started in 2000, 950+ Springboard portfolio companies have created more than $76B in value, 28 IPOs, and 10 unicorns.